GLP-1类似物利司那肽通过调节巨噬细胞表型减轻胰岛素抵抗小鼠的动脉粥样硬化
在Apoe-/-Irs2+/-胰岛素抵抗小鼠模型中,利司那肽或利拉鲁肽改善糖代谢和血压且不依赖体重下降,两者均显著缩小动脉粥样斑块。利司那肽使斑块更稳定、炎症浸润更少,体外实验显示其减少巨噬细胞IL-6分泌并促进M2表型极化。
要点
- 利司那肽和利拉鲁肽均改善Apoe-/-Irs2+/-小鼠糖代谢和血压,不依赖体重下降。
- 两药均显著缩小动脉粥样斑块;利司那肽使斑块更稳定、炎症浸润更少。
- 利司那肽减少巨噬细胞IL-6分泌,促进STAT3活化及M2表型极化。
核心结论
- 利司那肽通过将巨噬细胞重编程为M2表型减少炎症,从而缩小Apoe-/-Irs2+/-小鼠的动脉粥样斑块并降低不稳定性。
研究设计与样本
- 在Apoe-/-Irs2+/-小鼠(胰岛素抵抗、代谢综合征和动脉粥样硬化模型)中评估利司那肽或利拉鲁肽对动脉粥样硬化发展的影响。
- 在Apoe-/-Irs2+/-小鼠及小鼠来源巨噬细胞中研究利司那肽对潜在炎症细胞内通路的作用。
主要发现
- 利司那肽或利拉鲁肽改善Apoe-/-Irs2+/-小鼠糖代谢和血压,且不依赖体重下降。
- 两种药物均显著缩小动脉粥样斑块大小。
- 与溶媒对照小鼠相比,利司那肽治疗产生更稳定的斑块,炎症浸润更少、坏死核心减少、纤维帽更厚。
- 利司那肽治疗小鼠IL-6水平、促炎Ly6Chigh单核细胞和活化T细胞均减少。
- 体外实验显示利司那肽减少Apoe-/-Irs2+/-小鼠巨噬细胞促炎细胞因子IL-6分泌,伴STAT3活化增强、STAT1活化减弱。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Recent clinical studies indicate that glucagon-like peptide-1 (GLP-1) analogues prevent acute cardiovascular events in type 2 diabetes mellitus but their mechanisms remain unknown. In the present study, the impact of GLP-1 analogues and their potential underlying molecular mechanisms in insulin resistance and atherosclerosis are investigated. METHODS: Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide. In addition, studies in Apoe -/- Irs2 +/- mice and mouse-derived macrophages treated with lixisenatide were performed to investigate the potential inflammatory intracellular pathways. RESULTS: Treatment of Apoe -/- Irs2 +/- mice with either lixisenatide or liraglutide improved glucose metabolism and blood pressure but this was independent of body weight loss. Both drugs significantly decreased atheroma plaque size. Compared with vehicle-treated control mice, lixisenatide treatment generated more stable atheromas, with fewer inflammatory infiltrates, reduced necrotic cores and thicker fibrous caps. Lixisenatide-treated mice also displayed diminished IL-6 levels, proinflammatory Ly6Chigh monocytes and activated T cells. In vitro analysis showed that, in macrophages from Apoe -/- Irs2 +/- mice, lixisenatide reduced the secretion of the proinflammatory cytokine IL-6 accompanied by enhanced activation of signal transducer and activator of transcription (STAT) 3, which is a determinant for M2 macrophage differentiation. STAT1 activation, which is essential for M1 phenotype, was also diminished. Furthermore, atheromas from lixisenatide-treated mice showed higher arginase I content and decreased expression of inducible nitric oxide synthase, indicating the prevalence of the M2 phenotype within plaques. CONCLUSIONS/INTERPRETATION: Lixisenatide decreases atheroma plaque size and instability in Apoe -/- Irs2 +/- mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation. This study identifies a critical role for this drug in macrophage polarisation inside plaques and provides experimental evidence supporting a novel mechanism of action for GLP-1 analogues in the reduction of cardiovascular risk associated with insulin resistance.
引用
- Vinué Á, Navarro J, Herrero-Cervera A, et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia. 2017. PMID: 28608285. doi:10.1007/s00125-017-4330-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。